Market Closed -
Japan Exchange
07:00:00 15/05/2024 BST
|
5-day change
|
1st Jan Change
|
242
JPY
|
-0.41%
|
|
-4.72%
|
+28.72%
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9,754
|
-
|
-
|
Enterprise Value (EV)
1 |
9,754
|
9,754
|
9,754
|
P/E ratio
|
-111
x
|
-7.56
x
|
-7.56
x
|
Yield
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.9
x
|
-
|
-
|
EV / Revenue
|
13.9
x
|
-
|
-
|
EV / EBITDA
|
-10.3
x
|
-7.71
x
|
-7.56
x
|
EV / FCF
|
-115
x
|
-10.8
x
|
-7.5
x
|
FCF Yield
|
-0.87%
|
-9.23%
|
-13.3%
|
Price to Book
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
40,304
|
-
|
-
|
Reference price
2 |
242.0
|
242.0
|
242.0
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Net sales
1 |
700
|
-
|
-
|
EBITDA
1 |
-950
|
-1,265
|
-1,290
|
EBIT
1 |
-85.1
|
-1,275
|
-1,300
|
Operating Margin
|
-12.16%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-79
|
-1,275
|
-1,300
|
Net income
1 |
-80
|
-1,275
|
-1,300
|
Net margin
|
-11.43%
|
-
|
-
|
EPS
2 |
-2.190
|
-32.00
|
-32.00
|
Free Cash Flow
1 |
-84.9
|
-900
|
-1,300
|
FCF margin
|
-12.13%
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
Fiscal Period: February |
2024 Q4
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
|
-
|
Net margin
|
-
|
EPS
1 |
13.23
|
Dividend per Share
|
-
|
Announcement Date
|
-
|
Fiscal Period: February |
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
1 |
-84.9
|
-900
|
-1,300
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
Capex
1 |
10
|
10
|
10
|
Capex / Sales
|
1.43%
|
-
|
-
|
Announcement Date
|
-
|
-
|
-
|
Average target price
760
JPY Spread / Average Target +214.05% Consensus |
1st Jan change
|
Capi.
|
---|
| +28.72% | 62.61M | | +29.56% | 49.18B | | +0.61% | 42.11B | | +50.47% | 40.37B | | -5.26% | 28.85B | | +13.66% | 26.09B | | -22.76% | 18.71B | | +7.96% | 13.26B | | +32.19% | 12.32B | | -1.50% | 11.99B |
Other Biotechnology & Medical Research
|